Cellular immunotherapy for soft tissue sarcomas

Immunotherapy

Volumn 4, Issue 3, 2012, Pages 283-290

  Finkelstein, Steven Eric ^b   Fishman, Mayer ^a   Conley, Anthony P ^a   Gabrilovich, Dmitry ^a   Antonia, Scott ^a   Chiappori, Alberto ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b 21ST CENTURY ONCOLOGY   (United States)

Author keywords

cytotoxic T lymphocyte; dendritic cell; immune specific response; immunotherapy; intratumoral; neoadjuvant; radiation therapy; soft tissue sarcoma

Indexed keywords

CORTICOSTEROID; CYTOKINE; DENDRITIC CELL VACCINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; INTERLEUKIN 2; NY ESO 1 ANTIGEN; PACLITAXEL; SURVIVIN; T LYMPHOCYTE RECEPTOR; TAXANE DERIVATIVE; TUMOR VACCINE;

ANTINEOPLASTIC ACTIVITY; BLOOD VESSEL; BONE MARROW; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL KILLING; CELL LYSATE; CLINICAL TRIAL (TOPIC); COLLIMATOR; COLON CANCER; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DRUG TOLERANCE; EXTERNAL BEAM RADIOTHERAPY; FIBROMA; GAMMA IRRADIATION; GENE THERAPY; GLIOBLASTOMA; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LEUKAPHERESIS; LUNG CANCER; LUNG METASTASIS; LYMPH NODE; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; METASTASIS RESECTION; MULTIMODALITY CANCER THERAPY; MYELOID DENDRITIC CELL; NERVE; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SALVAGE THERAPY; SKELETAL MUSCLE; SMOOTH MUSCLE; SOFT TISSUE SARCOMA; SUPPRESSOR CELL; SYNOVIAL SARCOMA; SYNOVIUM; SYSTEMIC DISEASE; TENDON; TUMOR CELL; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

ANTIGENS, NEOPLASM; CANCER VACCINES; CELL TRANSPLANTATION; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; NEOPLASM METASTASIS; SARCOMA; TISSUE THERAPY;

EID: 84858301128     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.3     Document Type: Review

References (33)

1. Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am. J. Clin. Oncol. 21(3), 317-321 (1998). (Pubitemid 28280151)
2. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29(7), 917-924 (2011).
3. Gabrilovich DI. Dendritic cell vaccines for cancer treatment. Curr. Opin Mol. Ther. 4(5), 452-458 (2002). (Pubitemid 36305037)
4. Steinman RM, Inaba K, Turley S, Pierre P, Mellman I. Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum. Immunol. 60(7), 562-567 (1999). (Pubitemid 29328610)
5. Nouri-Shirazi M, Banchereau J, Bell D, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J. Immunol. 165(7), 3797-3803 (2000). (Pubitemid 32057286)
6. Restifo NP. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr. Opin Immunol. 12(5), 597-603 (2000).
7. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767-811 (2000). (Pubitemid 30365397)
8. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392(6673), 245-252 (1998). (Pubitemid 28155090)
9. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264(5161), 961-965 (1994). (Pubitemid 24196166)
10. Sotomayor EM, Borrello I, Rattis FM, et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98(4), 1070-1077 (2001).
11. Gabrilovich D, Pisarev V. Tumor escape from immune response: mechanisms and targets of activity. Curr. Drug Targets 4(7), 525-536 (2003). (Pubitemid 37139048)
12. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 191(3), 411-416 (2000).
13. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol. 12(11), 1539-1546 (2000).
14. Maity A, McKenna WG, Muschel RJ. The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother. Oncol. 31(1), 1-13 (1994). (Pubitemid 24167585)
15. Mashiba H, Matsunaga K, Hata K. Enhancement of radiosensitizing effect of the nitroimidazole derivative RK28 on the proliferation of MethA tumor cells in combined use with diethyldithiocarbamate. Life Sci. 49(19), 1419-1425 (1991).
16. Candido KA, Shimizu K, McLaughlin JC, et al. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res. 61(1), 228-236 (2001). (Pubitemid 32095722)
17. Nikitina EY, Gabrilovich DI. Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int. J. Cancer 94(6), 825-833 (2001). (Pubitemid 33032831)
18. Teitz-Tennenbaum S, Li Q, Rynkiewicz S, et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res. 63(23), 8466-8475 (2003). (Pubitemid 37549503)
19. Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res. 61(20), 7530-7535 (2001). (Pubitemid 32995044)
20. Yu B, Kusmartsev S, Cheng F, et al. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin. Cancer Res. 9(1), 285-294 (2003). (Pubitemid 36109745)
21. Song W, Levy R. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. Cancer Res. 65(13), 5958-5964 (2005). (Pubitemid 40911203)
22. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
23. Finkelstein SE, Timmerman R, McBride WH, et al. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin. Dev. Immunol. 2011, 439752 (2011).
24. Ardon H, Van Gool S, Lopes IS, et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J. Neurooncol. 99(2), 261-272 (2010).
25. Fadul CE, Fisher JL, Hampton TH, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J. Immunother. 34(4), 382-389 (2011).
26. Finkelstein SE, Gabrilovich DI, Bui MM, et al. At the confluence of radiation therapy and immunotherapy: external beam radiation (EBRT) with intratumoral injection of dendritic cells as neoadjuvant treatment of high-risk soft tissue sarcoma patients. Int. J. Radiat. Oncol. 75(3 Suppl.), S65 (2009).
27. Finkelstein SE, Iclozan C, Bui MM, et al. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int. J. Radiat. Oncol. Biol. Phys. 82(2), 924-932 (2011).
28. Iclozan CD, Cotter MJ, Ramakrishnan R, et al. Myeloid-derived suppressor cell and regulatory T cell immune monitoring of soft tissue sarcoma patients undergoing combination external beam radiation and intratumoral dendritic cell vaccination. Int. J. Radiat. Oncol. 78(3), S657-S658 (2010).
29. Noyes DR, Lenox BC, Bui MM, et al. Serum IL-R1a and IP-10 cytokine/chemokine profiling differences in immune responders and non-responders to combination radiation/immunotherapy for soft tissue sarcoma. Int. J. Radiat. Oncol. 78(3), S85-S86 (2010).
30. Finkelstein SE, Rodriguez F, Dunn M, et al. Knowing when to say when: prospective serial assessment of apoptosis, cell death, and lymphocyte infiltrates during the first clinical experience with intraprostatic autologous dendritic cell injection coordinated with radiation therapy. Immunotherapy (2012) (In Press).
31. Finkelstein SE, Timmerman R, McBride WH, et al. The confluence of stereotactic ablative radiotherapy (SABR) and tumor immunology. Clin. Dev. Immunol. 2011, 439752 (2011).
32. External Beam Radiation With Intratumoral Injection Of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma. http://clinicaltrials.gov/ct2/show/ NCT00365872
33. Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS). http://clinicaltrials.gov/ct2/show/ NCT01347034